IBDEI1S7 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,31835,0)
 ;;=C78.7^^190^1943^132
 ;;^UTILITY(U,$J,358.3,31835,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31835,1,3,0)
 ;;=3^Malig Neop Liver/Intrahepatic Bile Duct,Secondary
 ;;^UTILITY(U,$J,358.3,31835,1,4,0)
 ;;=4^C78.7
 ;;^UTILITY(U,$J,358.3,31835,2)
 ;;=^5001339
 ;;^UTILITY(U,$J,358.3,31836,0)
 ;;=C79.71^^190^1943^145
 ;;^UTILITY(U,$J,358.3,31836,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31836,1,3,0)
 ;;=3^Malig Neop Right Adrenal Gland,Secondary
 ;;^UTILITY(U,$J,358.3,31836,1,4,0)
 ;;=4^C79.71
 ;;^UTILITY(U,$J,358.3,31836,2)
 ;;=^5001356
 ;;^UTILITY(U,$J,358.3,31837,0)
 ;;=C78.01^^190^1943^148
 ;;^UTILITY(U,$J,358.3,31837,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31837,1,3,0)
 ;;=3^Malig Neop Right Lung,Secondary
 ;;^UTILITY(U,$J,358.3,31837,1,4,0)
 ;;=4^C78.01
 ;;^UTILITY(U,$J,358.3,31837,2)
 ;;=^5001335
 ;;^UTILITY(U,$J,358.3,31838,0)
 ;;=C79.70^^190^1943^101
 ;;^UTILITY(U,$J,358.3,31838,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31838,1,3,0)
 ;;=3^Malig Neop Adrenal Gland Unspec,Secondary
 ;;^UTILITY(U,$J,358.3,31838,1,4,0)
 ;;=4^C79.70
 ;;^UTILITY(U,$J,358.3,31838,2)
 ;;=^5001355
 ;;^UTILITY(U,$J,358.3,31839,0)
 ;;=C78.00^^190^1943^133
 ;;^UTILITY(U,$J,358.3,31839,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31839,1,3,0)
 ;;=3^Malig Neop Lung Unspec,Secondary
 ;;^UTILITY(U,$J,358.3,31839,1,4,0)
 ;;=4^C78.00
 ;;^UTILITY(U,$J,358.3,31839,2)
 ;;=^5001334
 ;;^UTILITY(U,$J,358.3,31840,0)
 ;;=D57.1^^190^1943^171
 ;;^UTILITY(U,$J,358.3,31840,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31840,1,3,0)
 ;;=3^Sickle-Cell Disease w/o Crisis
 ;;^UTILITY(U,$J,358.3,31840,1,4,0)
 ;;=4^D57.1
 ;;^UTILITY(U,$J,358.3,31840,2)
 ;;=^5002309
 ;;^UTILITY(U,$J,358.3,31841,0)
 ;;=D75.1^^190^1943^169
 ;;^UTILITY(U,$J,358.3,31841,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31841,1,3,0)
 ;;=3^Polycythemia,Secondary
 ;;^UTILITY(U,$J,358.3,31841,1,4,0)
 ;;=4^D75.1
 ;;^UTILITY(U,$J,358.3,31841,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,31842,0)
 ;;=C90.30^^190^1943^172
 ;;^UTILITY(U,$J,358.3,31842,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31842,1,3,0)
 ;;=3^Solitary Plasmacytoma,Not in Remission
 ;;^UTILITY(U,$J,358.3,31842,1,4,0)
 ;;=4^C90.30
 ;;^UTILITY(U,$J,358.3,31842,2)
 ;;=^5001759
 ;;^UTILITY(U,$J,358.3,31843,0)
 ;;=D56.3^^190^1943^173
 ;;^UTILITY(U,$J,358.3,31843,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31843,1,3,0)
 ;;=3^Thalassemia Minor
 ;;^UTILITY(U,$J,358.3,31843,1,4,0)
 ;;=4^D56.3
 ;;^UTILITY(U,$J,358.3,31843,2)
 ;;=^340497
 ;;^UTILITY(U,$J,358.3,31844,0)
 ;;=D56.9^^190^1943^174
 ;;^UTILITY(U,$J,358.3,31844,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31844,1,3,0)
 ;;=3^Thalassemia,Unspec
 ;;^UTILITY(U,$J,358.3,31844,1,4,0)
 ;;=4^D56.9
 ;;^UTILITY(U,$J,358.3,31844,2)
 ;;=^340606
 ;;^UTILITY(U,$J,358.3,31845,0)
 ;;=M31.1^^190^1943^176
 ;;^UTILITY(U,$J,358.3,31845,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31845,1,3,0)
 ;;=3^Thrombotic Microangiopathy
 ;;^UTILITY(U,$J,358.3,31845,1,4,0)
 ;;=4^M31.1
 ;;^UTILITY(U,$J,358.3,31845,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,31846,0)
 ;;=D51.2^^190^1943^177
 ;;^UTILITY(U,$J,358.3,31846,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31846,1,3,0)
 ;;=3^Transcobalamin II Deficiency
 ;;^UTILITY(U,$J,358.3,31846,1,4,0)
 ;;=4^D51.2
 ;;^UTILITY(U,$J,358.3,31846,2)
 ;;=^5002286
 ;;^UTILITY(U,$J,358.3,31847,0)
 ;;=D05.92^^190^1943^31
 ;;^UTILITY(U,$J,358.3,31847,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31847,1,3,0)
 ;;=3^Carcinoma in Situ Left Breast,Unspec Type
 ;;^UTILITY(U,$J,358.3,31847,1,4,0)
 ;;=4^D05.92
 ;;^UTILITY(U,$J,358.3,31847,2)
 ;;=^5001937
